HONG KONG – YL Biologics Ltd. has inked a licensing deal to distribute a biosimilar for the treatment of anemia by Korea’s CJ Healthcare Ltd. in Japan. The drug, CJ-40001, is CJ Healthcare’s version of Amgen Inc.’s Aranesp (darbepoetin alfa).